Met-097i
Metsera公布MET-097i IIb期顶线数据，辉瑞73亿美元收购加速全球III期临床启动
Metsera发布超长效GLP-1候选药MET-097i在VESPER-1和VESPER-3 IIb期临床数据：28周注射最高体重下降14.1%，耐受性良好。VESPER-1总中断率仅2.9%。基于此，全球III期临床将于2025年底启动，同时支撑辉瑞73亿美元收购布局。
Met-097i
Met-097i
Pfizer’s $7.3B Obesity Gamble Pays Early with MET-097i Phase 2b Success
Pfizer’s $7.3 billion acquisition of Metsera is backed by new Phase 2b data for MET-097i, an ultra-long-acting GLP-1 candidate showing 14% weight loss and promising tolerability. Phase 3 initiation is slated for late 2025. Monthly dosing could give Pfizer an edge in the obesity race.
Metsera
辉瑞73亿美元收购Metsera，布局潜在月度给药的新一代减肥疗法
辉瑞 ($PFE) 宣布将收购 Metsera ($MTRS)，交易总价值最高达 73 亿美元，获得其核心资产 MET-097i，这是一款新一代 GLP-1 受体激动剂，超长效、可潜在月度给药，12 周体重下降可达 11.3%，耐受性良好。
Metsera
Pfizer Finalizes $7.3B Metsera Buy for Next-Gen Obesity Therapy with Monthly Dosing
fizer has entered into a definitive agreement to acquire Metsera for up to $7.3B, gaining MET-097i, a next-gen GLP-1 therapy with ultra-long acting, potentially monthly dosing, strong Phase 2a efficacy, and promising tolerability.